Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Patients with diabetes have poorer cardiac surgery outcomes compared with non-diabetics.
Proper blood glucose management is critical to reduce the morbidity and mortality for
diabetic patients after cardiac surgery.
SGLT2 inhibitors including dapagliflozin as a new diabetes drug can reduce heart failure
hospitalization rates and overall cardiovascular mortality in patients with cardiovascular
disease.
This study is to assess the impact of one year of treatment of SGLT2 inhibitors on cardiac
function, postoperative complications and long-term cardiovascular mortality in diabetic
patients undergoing cardiac surgery.
The investigators use echocardiography to evaluated cardiac function in diabetic patients
during perioperative cardiac surgery.